Emerging drugs in pancreatic cancer

Expert Opinion on Emerging Drugs

Volumn 9, Issue 1, 2004, Pages 73-89

  Ducreux, Michel ^a   Boige, Valérie ^a   Malka, David ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Drug therapy; Immunotherapy; Pancreatic neoplasms; Radiotherapy

Indexed keywords

2,3,5 TRIMETHYL 6 (3 PYRIDYLMETHYL) 1,4 BENZOQUINONE; 4 N ACETYLDINALINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; DALTEPARIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; EPIRUBICIN; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; ISIS 2503; LIPOXYGENASE INHIBITOR; LONAFARNIB; MATRIX METALLOPROTEINASE INHIBITOR; MITOMYCIN C; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; PLEVITREXED; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RALTITREXED; RUBITECAN; TANOMASTAT; TEGAFUR; TIPIFARNIB; TRIACETYLURIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE DERIVATIVE; VIRULIZIN;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG POTENTIATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; INTESTINE PERFORATION; NEUROPATHY; NEUTROPENIA; PANCREAS CANCER; PANCREAS SURGERY; REVIEW; THROMBOCYTOPENIA; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; ENZYME INHIBITORS; FEMALE; FLUOROURACIL; GROWTH INHIBITORS; HUMANS; IMMUNOTHERAPY; MALE; MULTICENTER STUDIES; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; ORGANOPLATINUM COMPOUNDS; PANCREATECTOMY; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RECEPTORS, GROWTH FACTOR; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 2642572642     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.9.1.73     Document Type: Review

References (167)

1. EVANS DB, ABBRUZZESE JL, WILLETT CG: Cancer of the pancreas. In: Cancer: Principles and Practice of Oncology. DeVita VTJ, Hellman S, Rosenberg SA (Eds.), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2001):1126-1161.
2. BRAMHALL, SR, ALLUM WH, JONES AG, ALLWOOD A, CUMMINS C, NEOPTOLEMOS JP: Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br. J. Surg. (1995) 82(1):111-115.
3. BRAMHALL SR, DUNN J, NEOPTOLEMOS JP: Epidemiology of pancreatic cancer In: The Pancreas. Beger HG, Warshaw A, Carr-Locke DL (Eds), Blackwell Scientific, Boston, MA, USA (1998):889-906.
4. FERNANDEZ E, LA VECCHIA C, PORTA M, NEGRI E, LUCCHINI F, LEVI F: Trends in pancreatic cancer mortality in Europe, 1955-1989. Int. J. Cancer (1994) 57(6):786-792.
5. JEMAL A, THOMAS A, MURRAY T, THUN M: Cancer statistics 2002. CA Cancer J. Clin (2002) 52(1):23-47.
6. PARKIN DM, BRAY FI, DEVESA SS: Cancer burden in the year 2000. The global picture. Eur. J. Cancer (2001) 37(Suppl. 8):S4-S66.
7. FERLAY J, BRAY F, PISANI P, PARKIN DM: GLOBOSCAN 2000: Cancer incidence, mortality and prevalence worldwide, version 1.0.IARC Press. Cancer Base (2001).
8. LOWENFELS AB, MAISONNEUVE P, CAVALLINI G et al.: Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N. Engl. J. Med (1993) 328:1433-1437.
9. LOWENFELS AB, MAISONNEUVE P, DIMAGNO EP et al.: Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J. Natl. Cancer Inst. (1997) 89(6):442-446.
10. MALKA D, HAMMEL P, MAIRE F et al.: Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut (2002) 51(6):849-852.
11. WONG T, HOWES N, THREADGOLD J et al.: Molecular diagnosis of early pancreatic ductal adenocarcinoma in high-risk patients. Pancreatology (2001) 1(5):486-509.
12. COUGHLIN SS, CALLE EE, PATEL AV, THUN MJ: Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control (2000) 11(10):915-923.
13. HARNACK LJ, ANDERSON KE, ZHENG W, FOLSOM AR, SELLERS TA, KUSHI LH: Smoking, alcohol, coffee, and tea intake and incidence of cancer of the exocrine pancreas: the Iowa Women's Health Study. Cancer Epidemiol. Biomarkers Prev. (1997) 6(12):1081-1086.
14. LOWENFELS AB, MAISONNEUVE P, WHITCOMB DC, LERCH MM, DIMAGNO EP: Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA (2001) 286(2):169-170.
15. HAYCOX A, LOMBARD M, NEOPTOLEMOS J, WALLEY T: Review article: current practice and future perspectives in detection and diagnosis of pancreatic cancer. Aliment. Pharmacol. Ther. (1998) 12(10):937-948.
16. MAGEE CJ, GREENHALF W, HOWES N, GHANEH P, NEOPTOLEMOS JP: Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications. Surg. Oncol. (2001) 10(1-2):1-23.
17. EDIS AJ, KIERNAN PD, TAYLOR WF: Attempted curative resection of ductal carcinoma of the pancreas. Review of Mayo Clinic Experience, 1951-1975. Mayo Clin. Proc. (1980) 55:531-536.
18. JANES RH, NIEDERHUBER JE, CHMIEL JS et al.: National patterns of care for pancreatic cancer. Results of a survey by the commission on cancer. Ann. Surg. (1996) 223(3):261-272.
19. MANABE T, OHSHIO G, BABA N et al.: Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer (1989) 64:1132-1137.
20. BAUMEL H, HUGUIER M, MANDERSCHEID JC, FABRE JM, HOURY S, FAGOT H: Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery. Br. J. Surg. (1994) 81(1):102-107.
21. HALLER DG: Chemotherapy for advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. (2003) 56(Suppl 4):16-23.
22. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group. J. Clin. Oncol. (1986) 4(12):1794-1798.
23. BURRIS HAI, MOORE JA, ANDERSEN J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer a randomized trial. J. Clin. Oncol. (1997) 15:2403-2413. This landmark randomised trial established gemcitabine as the standard first-line therapy for advanced PDA.
24. OSTER MW, GRAY R, PANASCI L, PERRY MC: Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer (1986) 57(1):29-33.
25. PLUNKETT W, HUANG P, GANDHI V: Preclinical characteristics of gemcitabine. Anticancer Drugs (1995) 6(Suppl.):7-13.
26. CARMICHAEL J, FINK U, RUSSELL RC et al.: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer (1996) 73(1):101-105.
27. CASPER ES, GREEN MR, KELSEN DP et al.: Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs (1994) 12(1):29-34.
28. HUANG P, CHUBB S, HERTEL LW, GRINDEY GB, PLUNKETT W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. (1991) 51(22):6110-6117.
29. LOUVET C, LABIANCA R, HAMMEL P et al.: Gemcitabine versus GEMOX (gemcitabine + oxaliplatin) in non resectable pancreatic adenocarcinoma: interim results of the GERCOR/GISCAD intergroup phase III. Proc. Am. Soc. Clin. Oncol. (2003) 22:250 (Abstract). Preliminary results of a randomised trial suggesting that gemcitabine plus oxaliplatin could become a new standard for first-line therapy of advanced PDA.
30. TOUROUTOGLOU N, GRAVEL D, RABER MN, PLUNKETT W, ABBRUZZESE JL: Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol. (1998) 9(9):1003-1008.
31. TEMPERO M, PLUNKETT W, RUIZ VH et al.: Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J. Clin. Oncol. (2003) 21(18):3402-3408. A basis for considering fixed dose rate infusion as a potential new standard for administration of gemcitabine.
32. CARTER SK, COMIS RL: The integration of chemotherapy into a combined modality approach for cancer treatment VI. Pancreatic adenocarcinoma. Cancer Treat. Rev. (1975) 2(3):193-214.
33. DUCREUX M, ROUGIER P, PIGNON J-P et al.: A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann. Oncol. (2002) 13:1185-1191. A large randomised trial showing that 5-FU is ineffective, and that the benefit conferred by the addition of cisplatin is counterbalanced by increased toxicity.
34. GLIMELIUS B, HOFFMAN K, SJODEN PO et al.: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol. (1996) 7(6):593-600. This study established palliative chemotherapy as a standard over best supportive care in advanced PDA.
35. MALLINSON CN, RAKE MO, COCKING JB et al.: Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomized, multicentre trial. Br. Med. J. (1980) 281(6255):1589-1591.
36. PALMER KR, KERR M, KNOWLES G, CULL A, CARTER DC, LEONARD RC: Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br. J. Surg. (1994) 81:882-885.
37. CULLINAN S, MOERTEL CG, WIEAND HS et al.: A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer (1990) 65:2207-2212.
38. AUERBACH M, WAMPLER GL, LOKICH JJ, FRYER D, FRYER JG, AHLGREN JD: Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: a Mid-Atlantic Oncology Program Study. Ann. Oncol. (1997) 8(5):439-444.
39. MAISEY N, CHAU I, CUNNINGHAM D et al.: Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J. Clin. Oncol. (2002) 20(14):3130-3136.
40. LOUVET C, BEERBLOCK K, DE GRAMONT A et al.: High-dose folinic acid, 5-fluorouracil bolus and infusion in advanced pancreatic adenocarcinoma: a pilot study. Eur. J. Cancer (1993) 29A:1217 (letter).
41. MATANO E, TAGLIAFERRI P, LIBROIA A et al.: Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented Phase II study. Br. J. Cancer (2000) 82(11):1772-1775.
42. OETTLE H, PELZER U, HOCHMUTH K et al.: Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer. Anticancer Drugs (1999) 10(8):699-704.
43. RAUCH DP, MAURER CA, AEBI S et al.: Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer. Oncology (2001) 60(1):43-48.
44. BERLIN JD, CATALANO P, THOMAS JP, KUGLER JW, HALLER DG, BENSON AB: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. (2002) 20(15):3270-3275.
45. BERLIN JD, ALBERTI DB, ARZOOMANIAN RZ et al.: A Phase 1 study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors. Invest. New Drugs (1998) 16(4):325-330.
46. POPLIN E, ROBERTS J, TOMBS M, GRANT S, RUBIN E: Leucovorin, 5-fluorouracil, and gemcitabine: a Phase I study. Invest. New Drugs (1999) 17(1):57-62.
47. BURCH PA, BLOCK M, SCHROEDER G et al.: Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study. Clin. Cancer Res. (2000) 6(9):3486-3492.
48. ANONYMOUS: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J. Clin. Oncol. (1998) 16:301-308.
49. EL-RAYES BF, ZALUPSKI MM, SHIELDS AF et al.: Phase II study of gemcitabine, cisplatin and infusional fluorouracil in advanced pancreatic cancer. J. Clin. Oncol. (2003) 21:2920-2925.
50. RENI M, PASSONI P, PANUCCI MG et al.: Definitive results of a Phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J. Clin. Oncol. (2001) 19(10):2679-2686.
51. PAZDUR R, HOFF PM, MEDGYESY D, ROYCE M, BRITO R: The oral fluomuracil prodrugs. Oncology (Huntingt.) (1998) 12(10, Suppl. 7):48-51.
52. ISHIKAWA T, UTOH M, SAWADA N et al.: Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem. Pharmacol. (1998) 55(7):1091-1097.
53. MIWA M, URA M, NISHIDA M et al.: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer (1998) 34(8):1274-1281.
54. CARTWRIGHT TH, COHN A, VARKEY JA et al.: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J. Clin. Oncol. (2002) 20(1):160-164.
55. SCHEITHAUER W, KORNEK GV, RADERER M et al.: Randomized multicenter Phase II trial of two different schedules of capedtabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. (2003) 21(7):1307-1312.
56. TWELVES C, HARPER P VAN CUTSEM E et al.: A phase III trial (SO14796) of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:263a.
57. O'SHAUGHNESSY J, MILES D, VUKELJA S et al.: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J. Clin. Oncol. (2002) 20(12):2812-2823.
58. UENO H, OKADA S, OKUSAKA T, IKEDA M, KURIYAMA H: Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer. Oncology (2002) 62(3):223-227.
59. FELIU J, LOPEZ ALVAREZ MP, JARAIZ MA et al.: Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma. The ONCOPAZ Cooperative Group. Cancer (2000) 89(8):1706-1713.
60. COLUCCI G, GIULIANI F, GEBBIA V et al.: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized Phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer (2002) 94(4):902-910.
61. HEINEMANN V, QUIETZSCH D, GIESELER F et al.: A Phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancratic carcinoma. Proc. Am. Soc. Clin. Oncol. (2003) 22:250 (Abstract).
62. DUCREUX M, MITRY E, OULD-KACI M et al.: Randomized Phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann. Oncol. (2004) 15(3):467-473.
63. CONROY T, PAILLOT B, FRANCOIS E et al.: Irinotecan (CPT-11), oxaliplatin (L-OHP) plus 5-FU/leucovorin (5FU/LV) as first line chemotherapy in patients (pts) with advanced pancreatic adenocarcinoma (APA). Proc. Am. Soc. Clin. Oncol. (2002) 21:147.
64. FAIVRE S, LE CHEVALIER T, MONNERAT C et al.: Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann. Oncol. (2002) 13(9):1479-1489.
65. LOUVET C, ANDRE T, LLEDO G et al.: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter Phase II study. J. Clin. Oncol. (2002) 20(6):1512-1518.
66. ALBERTS SR, TOWNLEY PM, GOLDBERG RM et al.: Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group Phase II study. Ann. Oncol. (2003) 14(4):580-585.
67. ROCHA LIMA CM, SAVARESE D, BRUCKNER H et al.: Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J. Clin. Oncol. (2002) 20(5):1182-1191.
68. ROCHA LIMA CMS, ROTCHE R, JEFFERY M et al.: A randomized Phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy. Proc. Am Soc. Clin. Oncol. (2003) 22:251.
69. STEHLIN JS, GIOVANELLA BC, NATELSON EA et al.: A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int. J. Oncol. (1999) 14(5):821-831. A Phase I trial suggesting that rubitecan may have promising efficacy in advanced PDA.
70. KONSTADOULAKIS MM, ANTONAKIS PT, TSIBLOULIS BG et al.: A Phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother. Pharmacol. (2001) 48(5):417-420.
71. D'ADAMO D, HAMMOND L, DONEHOWER R et al.: Final results of a Phase II study of DX-8951f (exatecan mesylate, DX) in advanced pancreatic cancer. Proc. Am Soc. Clin. Oncol. (2001) 20:134 (Abstract).
72. O'REILLY EM, ABOU-ALFA GK, HOFF P et al.: DX-8951f in advanced pancreatic cancer (APC). 2004 Gastrointestinal Cancers Symposium, San Francisco, LA, USA (2004) 138 (Abstract).
73. VEITIA R, DAVID S, BARBIER P et al.: Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel. Br. J. Cancer (2000) 83(4):544-549.
74. ROUGIER P, ADENIS A, DUCREUX M et al.: A Phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur. J. Cancer (2000) 36:1016-1025.
75. ANDROULAKIS N, KOUROUSIS C, DIMOPOULOS MA et al.: Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter Phase II study. J. Clin. Oncol. (1999) 17(6):1779-1785.
76. OKADA S, SAKATA Y, MATSUNO S et al.: Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Br. J. Cancer (1999) 80(3-4):438-443.
77. LUTZ MP, DUCREUX M, WAGENER T et al.: Docetaxel/gemcitabine or docetaxel/cisplatin in advanced pancreatic carcinoma: a randomized phase II study of the EORTC-GI group. Proc. Am. Soc. Clin. Oncol. (2002) 21:125 (Abstract).
78. SCHNEIDER BP, GANJOO KN, SEITZ DE et al.: Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology (2003) 65(3):218-223.
79. SHERMAN WH, FINE RL: Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. Oncology (2001) 60(4):316-321.
80. STATHOPOULOS GP, MAVROUDIS D, TSAVARIS N et al.: Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a Phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann. Oncol. (2001) 12(1):101-103.
81. KURTZ JE, ANDRES E, NATARAJAN-AME S, NOEL E, DUFOUR P: Oral chemotherapy in colorectal cancer treatment: review of the literature. Eur. J. Intern. Med. (2003) 14(1):18-25.
82. KRALIDIS E, AEBI S, FRIESS H, BUCHLER MW, BORNER MM: Activity of raltitrexed and gemcitabine in advanced pancreatic cancer. Ann. Oncol. (2003) 14(4):574-579.
83. VAN LAETHEM J-L, VAN MAELE P, POLUS M et al.: Raltitrexed (Tomudex) and gemcitabine (Gemzar) in advanced pancreatic carcinoma: a Belgian multicentre phase II study. Proc. Am. Soc. Clin. Oncol. (2002) 21:137 (Abstract).
84. MILLER KD, PICUS J, BLANKE C et al.: Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann. Oncol. (2000) 11(1):101-103.
85. KINDLER HL, DUGAN W, HOCHSTER H, STRICKLAND D, JACOBS A, JOHN WJ: Clinical outcome in patients (pts) with advanced pancreatic cancer treated with permetrexed/gemcitabine. Proc. Am. Soc. Clin. Oncol. (2002) 21:125 (Abstract).
86. SMITH D, GALLAGHER N: A Phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer. Eur. J. Cancer (2003) 39(10):1377-1383.
87. MOORE MJ, HAMM J, DANCEYJ et al.: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. (2003) 21(17):3296-3302. This randomised trial showed that the MMPI BAY12-9566 was inferior to gemcitabine in advanced PDA.
88. BRAMHALL SR, SCHULZ J, NEMUNAITIS J, BROWN PD, BAILLET M, BUCKELS JA: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer (2002) 87(2):161-167.
89. VAN CUTSEM E, KARASEK P, OETTLE H et al.: Phase III trial comparing gemcitabine + R115777 (Zamestra) versus gemcitabine + placebo in advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:130 (Abstract).
90. HURWITZ HI, AMADO R, PRAGER D: Phase I pharmacokinetic trial of the farnesyl transferase inhibitor SCH66366 plus gemcitabine in advanced cancers. Proc. Am. Soc. Clin. Oncol. (2000) 19:717 (Abstract).
91. LOBELL RB, OMER CA, ABRAMS MT et al.: Evaluation of farnesyl:protein tranfferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. (2001) 61(24):8758-8768.
92. KOKAWA A, KONDO H, GOTODA T et al.: Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer (2001) 91(2):333-338.
93. XIONG HQ, DU M, WOLFF RA et al.: Pharmacology study of celecoxib in combination with gemcitabine for advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:113 (Abstract).
94. SMITH SE, BURRIS HA, LOEHRER PJ et al.: Preliminary report of a Phase II trial of gemcitabine combined with celecoxib for advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:374 (Abstract).
95. LIPTON A, HARVEY H, WITTERS L, KERR S, LEGORE K, CAMPBELL C: Phase II trial of gemcitabine + irinotecan + celecoxib in pancreatic cancer. 2004 Gartrointestinal Cancers Symposium, San Francisco, LA, USA (2004) 153 (Abstract).
96. SAFRAN H, RAMANATHAN R, SCHWARTZ J et al.: Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Proc. Am. Soc. Clin. Oncol. (2001) 20:130a.
97. ABBRUZZESE JL, ROSENBERG A, XIONG Q et al.: Phase II study of anti-epidermal growth factor receptor (EGFR) antibody Cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2001) 20:130 (Abstract).
98. DRAGOVICH T, PATNAIK A, ROWINSKY EK et al.: A phase I B trial of gemcitabine and erlotinib HCL in patients with advanced pancreatic adenocarcinoma and other potentially responsive malignancies. Proc. Am. Soc. Clin. Oncol. (2003) 22:223 (Abstract).
99. MORGAN JA, BUKOWSKI RM, XIONG H et al.: Preliminary report of a phase 1 study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), given in combination with gemcitabine to patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:197 (Abstract).
100. KINDLER HL, ANSARI R, LESTER E et al.: Bevacizumab (B) plus gemcitabine (G) in patients (pts) with advnaced pancreatic cancer (PC). Proc. Am. Soc. Clin. Oncol. (2003) 22:259 (Abstract). Interim but promising results for bevacizumab-gemcitabine combination in advanced PDA.
101. KINDLER HL, FRIBERG G, STADLER WM et al.: Bevacizumab plus gemcitabine is an active combination in patients with advanced pancreatic cancer: interim results of an ongoing Phase II trial from the University of Chicago Phase II consortium. 2004 Gastrointestinal Cancers Symposium, San Francisco, LA, USA (2004) 86 (Abstract).
102. RYAN DP, EDER JP, WINKELMANN J et al.: Pharmacokinetic and pharmacodynamic Phase I study of PS-431 and gemcitabine in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21:95a.
103. RICHARDS DA, WAERHOUSE DM, WAGENER DTH et al.: Randomized, double-blind, placebo-controlled Phase 2 study of the histone deacetylase inhibitor CI-994 plus gemcitabine (CI-994+G) versus placebo plus gemcitabine (P+G) in the treatment of patients with advanced pancreatic cancer (APC). Proc. Am. Soc. Clin. Oncol. (2002) 21:162a.
104. FERRY DR, DEAKIN M, BADDELEY J et al.: A Phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Ann. Oncol. (2000) 11(9):1165-1170.
105. BURCH PA, ALBERTS SR, SCHROEDER MT et al.: Gemcitabine and ISIS-2503 for patients with pancreatic adenocarcinoma (ACA): a North Central Cancer Treatment Group (NCCTG) Phase II study. Proc. Am. Soc. Clin. Oncol. (2003) 22:259.
106. HANNA S, CHUNG T, HECHT JR et al.: Safety and efficacy of TNFerade in unresectable locally advanced pancreatic cancer: results of the first two cohorts of a dose escalating study. 2004 Gasrointestinal Cancers Symposium, San Francisco, LA, USA (2004) 84 (Abstract).
107. ICLI F, AKBULUT H, UTKAN G et al.: Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:286 (Abstract). Intriguing findings suggesting that LMWH may have efficacy in advanced PDA when combined with chemotherapy.
108. GJERTSEN MK, BAKKA A, BREIVIK J et al.: Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet (1995) 346(8987):1399-1400.
109. CHANG DZ, ABOU-ALFA GK, O'REILLY EM et al.: Vaccination of pancreatic cancer patients against mutated K-ras. Proc. Am. Soc. Clin. Oncol. (2003) 22: 285 (Abstract).
110. HAMILTON J, BEHRENS RJ, ACHTAR M et al.: An adjuvant Phase II pilot trial of mutant ras peptide vaccine in stage II and III pancreatic and Dukes C and D colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:186 (Abstract).
111. GAUDERNACK G, BUANES T, MEO M et al.: Clinical trials of a peptide based vaccine targeting telomerase. Proc. Am. Soc. Clin. Oncol. (2003) 22:166 (Abstract).
112. BRETT BT, SMITH SC, BOUVIER CV et al.: Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J. Clin. Oncol. (2002) 20(20):4225-4231. Promising results suggesting a potential therapeutic role for anti-gastrin antibodies in advanced PDA.
113. TALAMONTI MS, CATALANO PJ, VAUGHN DJ et al.: Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J. Clin. Oncol. (2000) 18(19):3384-3389.
114. MOERTEL CG, CHILDS DS, REITEMEIER RJ, COLBY MY, HOLBROOK MA: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet (1969) 2:865-867.
115. MOERTEL CG, FRYTAK S, HAHN RG et al.: Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 Rads) radiation alone, moderate dose radiation (4000 Rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The Gastrointestinal Tumor Study Group. Cancer (1981) 48:1705-1710.
116. MEHTA VK, POEN JC, FORD JM et al.: Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Am. J. Clin. Oncol. (2001) 24(2):155-159.
117. BOZ G, DE PAOLI A, INNOCENTE R et al.: Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. (2001) 51(3):736-740.
118. LUDERHOFF EC, GONZALEZ GD, BAKKER P: Pilot study in locally advanced unresectable pancreas carcinoma using a combination of accelerated radiotherapy and continuous infusion of 5-fluorouracil. Radiother. Oncol. (1996) 40(3):241-243.
119. PROTT FJ, SCHONEKAES K, PREUSSER P et al.: Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study. Br. J. Cancer (1997) 75(4):597-601.
120. PENBERTHY DR, RICH TA, SHELTON CH 3rd, ADAMS R, MINASI JS, JONES RS: A pilot study of chronomodulated infusional 5-fluorouracil chemoradiation for pancreatic cancer. Ann. Oncol. (2001) 12(5):681-684.
121. SHINCHI H, TAKAO S, NOMA H et al.: Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. (2002) 53(1):146-150. A randomised trial suggesting that 5-FU-based CRT may be superior to no CRT in locally advanced PDA.
122. OSTI MF, COSTA AM, BIANCIARDI F et al.: Concomitant radiotherapy with protracted 5-fluorouracil infusion in locally advanced carcinoma of the pancreas: a Phase II study. Tumori (2001) 87(6):398-401.
123. SAITO Y, MILROSS CG, HITTELMAN WN et al.: Effect of radiation and paclitaxel on p53 expression in murine tumors sensitive or resistant to apoptosis induction. Int. J. Radiat. Oncol. Biol. Phys. (1997) 38(3):623-631.
124. RICH TA, HARRIS J, ABRAMS R et al.: A Phase II study of external irradiation and weekly paclitaxel for non-metastatic, unresectable pancreatic cancer: a preliminary report of RTOG protocol 98-12. Int. J. Radiat. Oncol. Biol. Phys. (2001) 51:29.
125. WILLETT CG, SAFRAN H, ABRAMS RA, REGINE WF, RICH TA: Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials. Int. J. Radiat. Oncol. Biol. Phys. (2003) 56(Suppl. 4):31-37.
126. EPELBAUM R, ROSENBLATT E, NASRALLAH S et al.: Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J. Surg. Oncol. (2002) 81(3):138-143.
127. IKEDA M, OKADA S, TOKUUYE K, UENO H, OKUSAKA T: A Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br. J. Cancer (2002) 86(10):1551-1554.
128. MCGINN CJ, ZALUPSKI MM, SHUREIQI I et al.: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. (2001) 19(22):4202-4208.
129. HUANG NJ, HITTELMAN WN: Transient inhibition of chromosome damage repair after ionizing radiation by gemcitabine. Proc. Am. Assoc. Cancer Res. (2001) 36:612 (Abstract).
130. CRANE CH, WOLFF RA, ABBRUZZESE JL et al.: Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin. Oncol. (2001) 28(3, Suppl. 10):25-33.
131. MASON KA, MILAS L, HUNTER NR et al.: Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int. J. Radiat. Oncol. Biol. Phys. (1999) 44(5):1125-1135.
132. LI CP, CHAO Y, CHI KH et al.: Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int. J. Radiat. Oncol. Biol. Phys. (2003) 57(1):98-104. This randomised trial showed that gemcitabine-based CRT was superior to 5-FU-based CRT in locally advanced PDA.
133. HADDOCK MG, SWAMINATHAN R, ALBERTS SR, HAUGE MD, MARTENSON JA, FOSTER N: Phase II study of gemcitabine (Gem), cisplatin (Cis) and radiation therapy (RT) in patients with locally advanced pancreatic cancer A North Central Cancer Treatment Group (NCCTG) study. 2004 Gastrointestinal Cancers Symposium, San Francisco, LA, USA (2004).
134. Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group. Cancer (1985) 56:2563-2568.
135. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J. Natl. Cancer Inst. (1988) 80:751-755.
136. ISHII H, OKADA S, TOKUUYE K et al.: Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer (1997) 79(8):1516-1520.
137. KAMTHAN AG, MORRIS JC, DALTON J et al.: Combined modality therapy for stage II and stage III pancreatic carcinoma. J. Clin. Oncol. (1997) 15(8):2920-2927.
138. KLAASSEN DJ, MACINTYRE JM, CATTON GE, ENGSTROM PF, MOERTEL CG: Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil. An Eastern Cooperative Oncology Group study. J. Clin. Oncol. (1985) 3(3):373-378.
139. GRIFFIN JF, SMALLEY SR, JEWELL W et al.: Patterns of failure after curative resection of pancreatic carcinoma. Cancer (1990) 66(1):56-61.
140. GANSAUGE F, LINK KH, RILINGER N, KUNZ R, BEGER HG: Adjuvant regional chemotherapy in resected advanced pancreas carcinoma. Chirurg (1996) 67(4):362-365.
141. ISHIKAWA O, OHIGASHI H, SASAKI Y et al.: Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am. J. Surg. (1994) 168(4):361-364.
142. ISHIKAWA O, OHIGASHI H, IMAOKA S et al.: Regional chemotherapy to prevent hepatic metastasis after resection of pancreatic cancer. Hepatogastroenterology (1997) 44(18):1541-1546.
143. LINK KH, FORMENTINI A, GANSAUGE F, PAPACHRISTOV E, BEGER HG: Regional celiac artery infusion as adjuvant treatment after pancreatic cancer resection. Digestion (1997) 58(6):529-532.
144. BAKKEVOLD KE, ARNESJO B, DAHL O, KAMBESTAD B: Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater - results of a controlled, prospective, randomised multicentre study. Eur. J. Cancer (1993) 29A:698-703.
145. NEOPTOLEMOS JP, DUNN JA, STOCKEN DD et al.: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet (2001) 358(9293):1576-1585. This large, partially 2 x 2 factorial randomised trial suggested a survival benefit after adjuvant chemotherapy compared to surgery alone, but not after adjuvant CRT.
146. NEOPTOLEMOS JP, STOCKEN DD, DUNN JA et al.: Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann. Surg. (2001) 234(6):758-768.
147. ALFIERI S, MORGANTI AG, DI GIORGIO A et al.: Improved survival and local control after intraoperative radiation therapy and postoperative radiotherapy: a multivariate analysis of 46 patients undergoing surgery for pancreatic head cancer. Arch. Surg. (2001) 136(3):343-347.
148. JOHNSTONE PA, SINDELAR WF: Patterns of disease recurrence following definitive therapy of adenocarcinoma of the pancreas using surgery and adjuvant radiotherapy:correlations of a clinical trial. Int. J. Radiat. Oncol. Biol. Phys. (1993) 27(4):831-834.
149. LEE JH, WHITTINGTON R, WILLIAMS NN et al.: Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int. J. Radiat. Oncol. Biol. Phys. (2000) 47(4):945-953.
150. MEHTA VK, FISHER GA, FORD JM et al.: Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. (2000) 48(5):1483-1487.
151. WILLETT CG, LEWANDROWSKI K, WARSHAW AL, EFIRD J, COMPTON CC: Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann. Surg. (1993) 217(2):144-148.
152. KLINKENBIJL HL, JEEKEL J, SAHMOUD T et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann. Surg. (1999) 230:776-782.
153. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer (1987) 59:2006-2010.
154. KALSER MH, ELLENBERG SS: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg. (1985) 120:899-903.
155. ABRAMS RA, GROCHOW LB, CHAKRAVARTHY A et al.: Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int. J. Radiat. Oncol. Biol. Phys. (1999) 44(5):1039-1046.
156. PAULINO AC: Resected pancreatic cancer treated with adjuvant radiotherapy with or without 5-fluorouracil: treatment results and patterns of failure. Am. J. Clin. Oncol. (1999) 22(5):489-494.
157. SOHN TA, YEO CJ, CAMERON JL et al.: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J. Gastrointest. Surg. (2000) 4(6):567-579.
158. KACHNIC LA, SHAW JE, MANNING MA, LAUVE AD, NEIFELD JP: Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas. Int. J. Cancer (2001) 96(2):132-139.
159. BRESLIN TM, HESS KR, HARBISON DB et al.: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann. Surg. Oncol. (2001 8(2):123-132.
160. HOFFMAN JP, MCGINN CJ, SZARKA C et al.: A Phase I study of preoperative gemcitabine (GEM) with radiation therapy (RT) followed by postoperative GEM for patient with localized, resectable pancreatic adenocarcinoma (PAC). Proc. Am. Soc. Clin. Oncol. (1998) 17:283 (Abstract).
161. SNADY H, BRUCKNER H, COOPERMAN A, PARADISO J, KIEFER L: Survival advantage combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer (2000) 89(2):314-327.
162. COIA L, HOFFMAN J, SCHER R et al.: Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int. J. Radiat. Oncol. Biol. Phys. (1994) 30(1):161-167.
163. ISHIKAWA O, OHIGASHI H, IMAOKA S et al.: Is the long-term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head? Arch. Surg. (1994) 129(10):1075-1080.
164. WANEBO HJ, GLICKSMAN AS, VEZERIDIS MP et al.: Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch. Surg. (2000) 135(1):81-87.
165. SOHN TA, LILLEMOE KD, CAMERON JL et al.: Reexploration for periampullary carcinoma: resectability, perioperative results, pathology, and long-term outcome. Ann. Surg. (1999) 229(3):393-400.
166. GNANT M, KUEHRER I, TELEKY B et al.: Neoadjuvant chemotherapy of locally advanced pancreatic cancer leads to 67% 3-year survival. 2004 Gastrointestinal Cancers Symposium, San Francisco, LA, USA (2004) 98 (Abstract).
167. ASHAMALLA H, MOKHTAR B, DOSIK D, KRISHNAMURTHY M, COLELLA F: Hyperfractionated concomitant in-field boost with gemcytabine, paclitaxel followed by surgery in locally advanced pancreatic cancer. 2004 Gastrointestinal Cancers Symposium, San Francisco, CA, USA (2004) 158 (Abstract).